The world's first selective GLP-1 receptor agonist has started booking appointments on Ali Health.

On April 16th, the world's first selective GLP-1 receptor agonist, Semaglutide, started booking appointments on Ali Health. In February of this year, Pfizer China and Hangzhou Xianfada Biotechnology announced that they had reached a commercial strategic cooperation agreement on the new generation of selective GLP-1 receptor agonist Semaglutide. Currently, Semaglutide has completed strategic layout for the dual indications of "diabetes + weight loss".